We are live on ! Find out more
TA

Tamarack Advisers Portfolio holdings

AUM $2.12M
1-Year Est. Return 58.09%
This Fund
S&P 500
This Quarter Est. Return
+7.2%
1 Year Est. Return
-58.09%
3 Year Est. Return
-46.51%
5 Year Est. Return
+44.44%
10 Year Est. Return
–
AUM
$183M
AUM Growth
+$19.9M
Cap. Flow
+$7.39M
Cap. Flow %
4.03%
Top 10 Hldgs %
71.1%
Holding
42
New
10
Increased
11
Reduced
9
Closed
10

Top Buys

Rank Stock Value
1
NXTM
NxStage Medical Inc.
NXTM
+$7.25M
2
NVCR icon
NovoCure
NVCR
+$6M
3
QDEL icon
QuidelOrtho
QDEL
+$4.9M
4
DGX icon
Quest Diagnostics
DGX
+$4.74M
5
MCK icon
McKesson
MCK
+$3.7M

Top Sells

Rank Stock Value
1
NKTR icon
Nektar Therapeutics
NKTR
+$17.5M
2
CVS icon
CVS Health
CVS
+$6.1M
3
SRCL
Stericycle Inc
SRCL
+$4.17M
4
STE icon
Steris
STE
+$4.01M
5
XRAY icon
Dentsply Sirona
XRAY
+$2.99M

Sector Composition

Rank Sector Weight
1 Healthcare 92.06%
2 Industrials 3.25%
3 Consumer Discretionary 2.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HCA icon
26
CALL
HCA Healthcare
HCA
$87.2B
$845K 0.46%
1,000
-121
-11% -$9.72K
BSX icon
27
PUT
Boston Scientific
BSX
$69.5B
$328K 0.18%
+1,500
New +$41.4K
XLV icon
28
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$41.9B
$230K 0.13%
+2,000
New +$165K
SPY icon
29
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$795B
$168K 0.09%
4,000
– –
IWM icon
30
PUT
iShares Russell 2000 ETF
IWM
$80.2B
$96K 0.05%
+2,000
New +$300K
TMO icon
31
PUT
Thermo Fisher Scientific
TMO
$213B
$54K 0.03%
+100
New +$19.2K
SHPG
32
CALL
DELISTED
Shire pic
SHPG
$5K ﹤0.01%
394
-356
-47% -$52.8K
BAX icon
33
PUT
Baxter International
BAX
$13.5B
– –
-250
Closed -$18K
CVS icon
34
CVS Health
CVS
$133B
– –
-75,000
Closed -$6.1M
EVH icon
35
Evolent Health
EVH
$348M
– –
-75,000
Closed -$1.33M
HSIC icon
36
PUT
Henry Schein
HSIC
$9.77B
– –
-510
Closed -$286K
OEF icon
37
PUT
iShares S&P 100 ETF
OEF
$20.1B
– –
-4,500
Closed -$178K
SYK icon
38
PUT
Stryker
SYK
$125B
– –
-350
Closed -$193K
XRAY icon
39
Dentsply Sirona
XRAY
$2.68B
– –
-50,000
Closed -$2.99M
SIEN
40
DELISTED
Sientra, Inc.
SIEN
– –
-6,000
Closed -$924K
ESRX
41
CALL
DELISTED
Express Scripts Holding Company
ESRX
– –
-1,000
Closed -$510K
ALR
42
PUT
DELISTED
Alere Inc
ALR
– –
-1,000
Closed -$15K
1
2

Similar funds

SCM
SevenOneSeven Capital Management Lancaster, Pennsylvania $2.17M AUM 8.67% 1-Year Est. Return
LBC
Lawrence B. Cohen $2.06M AUM 34.47% 1-Year Est. Return
ICM
ISZO Capital Management New York $2M AUM 35.61% 1-Year Est. Return
LCMP
Linse Capital Management PR San Juan, Puerto Rico $2.31M AUM
GIP
General Industrial Partners London, United Kingdom $2.57M AUM
STC
Sarah T. Connolly $1.11M AUM 24.13% 1-Year Est. Return
GC
Gilfoyle & Co San Francisco, California $671K AUM
DU
Delphia (USA) Toronto, Ontario, Canada $445K AUM 28.82% 1-Year Est. Return

Tamarack Advisers's Q4 2017 Portfolio in Review

As of Q4 2017, Tamarack Advisers held 42 positions worth $183M, up 12% from $163M the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Tamarack Advisers deployed $7.39M of net new capital in Q4 2017, opening 10 new positions and adding to 11 existing holdings. Its largest new stake was NxStage Medical Inc.: 275,000 shares worth $6.66M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 93% a quarter earlier, followed by Industrials and Consumer Discretionary.

On the sell side, the largest reduction was Nektar Therapeutics, an estimated $17.5M trimmed.

  • Tamarack Advisers's largest Q4 2017 buy was NxStage Medical Inc.: 275,000 shares worth $6.66M.
  • Tamarack Advisers added most to NovoCure in Q4 2017, an estimated $6M increase.
  • Tamarack Advisers's biggest Q4 2017 reduction was Nektar Therapeutics, cutting an estimated $17.5M.
  • Tamarack Advisers fully exited CVS Health in Q4 2017, selling an estimated $6.1M.
  • Tamarack Advisers's ten largest holdings make up 71% of its $183M portfolio in Q4 2017.
  • Tamarack Advisers opened 10 new positions and closed 10 in Q4 2017.
  • Tamarack Advisers's portfolio value rose 12% quarter-over-quarter to $183M.

Based on Tamarack Advisers's 13F filing for Q4 2017, filed 14 Feb 2018.